Alvotech (ALVO) is a Luxembourg-domiciled biopharmaceutical company with its main research and manufacturing operations in Reykjavik, Iceland. It develops and manufactures biosimilars — near-copies of complex biologic medicines — including versions of Humira, Stelara, Simponi, Eylea and Prolia/Xgeva, and sells them through partners such as Teva and Advanz Pharma rather than a proprietary sales force. In late trading on Monday, the stock was at $4.42, a gain of 5.49% versus Friday's close of $4.19, confirming an upward move that interrupted a two-session decline of about 15%. No verified catalyst was found for the advance.
No verified news or fundamental catalyst found explains Monday's gain. There was no new corporate announcement, no securities filing, and no rating or target change dated to the session. The advance therefore looks technical in nature — most plausibly a rebound after the stock slid from $4.92 on Nov. 11 to $4.19 on Nov. 13, a cumulative drop of roughly 15% in two sessions on heavy volume of 1.7 million and 1.3 million shares.
Two data points support that read. First, Friday's close pushed the shares just below their 200-day moving average near $4.20, a level the stock reclaimed in Monday's session — a pattern consistent with buyers responding to a technical breakdown rather than to news. Second, this is a name that routinely swings by large amounts: its average absolute daily move over the last 60 sessions is about 3.3%, and eight of those sessions produced moves of 5.5% or more. A 5.5% advance is therefore unusually large relative to most stocks but unremarkable for Alvotech.
The decline that Monday's buying reversed was earnings-driven. Alvotech reported nine-month and third-quarter results after the close on Nov. 11: revenue of $111.6 million came in below consensus, adjusted EBITDA more than doubled year over year to $31.5 million, and product and service revenue rose 78% to $58.2 million. The friction came from cash, which fell to $61.5 million from $143 million at the end of the second quarter, and from guidance — management kept its 2026 revenue range of $650 million to $700 million and EBITDA of $180 million to $220 million but said results would land at the low end, implying a record fourth quarter.
The bull counterweight remains intact, which likely explains the willingness of dip-buyers to step in: October FDA approvals doubled US drug-substance capacity for Simlandi and cleared an enhanced manufacturing process, and three biosimilar applications carry December action dates. Jefferies initiated coverage with a Buy rating and a $9 target on Nov. 10, before the slide.
The move was a clear divergence from the surrounding tape. The S&P 500 proxy SPY fell about 2.0%, the biotech exchange-traded funds XBI and IBB dropped 2.8% and 1.9% respectively, and partner Teva Pharmaceutical fell 3.6%. Alvotech gained while all of them declined.
Participation was moderately elevated rather than explosive: roughly 750,000 shares had changed hands by late afternoon against a 60-session average near 625,000. The stock traded between $4.15 and $4.59, surrendering part of an early gain above 9%. Resistance sits near the 50-day average around $5.23, with support at the 200-day line near $4.20.
The score runs from 0, meaning no meaningful news and a move that is routine for the stock, to 100, meaning transformative news and an extreme, rare price move. Alvotech scores 12 out of 100.
Verified news strength was minimal: the only material development in the window was the Nov. 11 quarterly report, which was already reflected in two prior down sessions, so nothing new drove Monday. The price move was roughly 1.6 times the stock's typical daily swing, and larger moves occurred eight times in the last 60 sessions — a routine outcome for a heavily traded micro-cap with a light news calendar. Weak news plus an unremarkable move produces a low combined score.
The calendar is the story. Three biosimilar applications carry December FDA action dates, and the US launch of the Simponi biosimilar depends on a ruling in a pending preliminary-injunction motion, expected in the coming weeks. A Dec. 4 patent hearing governs the US path for the high-dose Eylea biosimilar. Fourth-quarter deliveries must also confirm management's record-quarter framing, while the cash position and any further financing remain the central balance-sheet risk. Analysts are split, with published ratings ranging from Buy to Sell.
Tickeron maintains hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions appear in its curated Trending AI Robots section. The bots differ by strategy, timeframe, performance metrics and the symbols they trade, so the list offers a practical starting point for comparing approaches rather than a single template. Reviewing the current leaders is a straightforward way to see which strategies are working in this tape.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where ALVO declined for three days, in 233 of 294 cases, the price declined further within the following month. The odds of a continued downward trend are 79%.
The Momentum Indicator moved below the 0 level on November 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ALVO as a result. In 71 of 99 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 72%.
The Moving Average Convergence Divergence Histogram (MACD) for ALVO turned negative on November 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 33 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 69%.
ALVO moved below its 50-day moving average on October 16, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ALVO crossed bearishly below the 50-day moving average on October 22, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 73%.
The Aroon Indicator for ALVO entered a downward trend on November 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ALVO's RSI Indicator exited the oversold zone, 25 of 35 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 71%.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +4.90% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALVO advanced for three days, in 199 of 269 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
ALVO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of 7 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-9.057) is normal, around the industry mean (6.379). P/E Ratio (-7.839) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (3.071) is also within normal values, averaging (183.387).
The Tickeron Price Growth Rating for this company is 60 (best 1 - 100 worst), indicating steady price growth. ALVO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALVO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry PharmaceuticalsGeneric